showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market ...

particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn ...

Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation.Data to be presented on ABBV ...

showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market ...

Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...